Commentary Regarding Mucositis during Cancer Therapy

Duration of Mucositis: Far Longer than 2 to 4 Weeks and May Be Avoidable Altogether

Ricky Wayne McCullough¹,², MD, MSc

¹Translational Medicine Research Center of Mueller Medical International Storrs-Mansfield CT 06268 USA

²Department of Medicine & Emergency Medicine Veterans Administration Medical Center, Teaching Hospital Warren Alpert Medical School of Brown University Providence, Rhode Island 02908 USA

Précis:
The impression oral mucositis is a brief consequence of chemoradiation is misguided. Patient-reported clinically significant oral mucositis may last 46 to 102 days depending on the cancer treatment, and may possibly be avoided with polymerized cross-linked sucralfate.

Keywords: Mucositis; Chemoradiation; Sucralfate; Polymerized Sucralfate.

Commentary Regarding Mucositis during Cancer Therapy

The oft-repeated refrain that “mucositis is self-limited when uncomplicated by infection and typically heals within 2 to 4 weeks after cessation of cytotoxic chemotherapy” or radiation [1], is an inexact statement that can be unintentionally disarming. It gives the impression that the duration of mucositis is short therefore tolerable particularly if there is no infection. Again, when referenced in material intended for patients [2], this statement is repackaged as follows: “In patients getting chemotherapy, mucositis will heal by itself when there is no infection. Healing usually takes 2 - 4 weeks.”

To be fair, the reference continues: “Mucositis caused by radiation therapy usually lasts 6 - 8 weeks”, which is closer to the reality, but is still far short of the 10-14 weeks required for the mucosa and mouth throat soreness to return to baseline [3, 4]. The impression that mucositis is a short-lived event is inaccurate, can be misleading and therefore detracts from appropriate clinical vigilance necessary to manage it.

Another impression given by these statements is that mucositis persisting beyond “2 to 4 weeks” is likely due to local infection which in turn should be suspected as the main driver of the mucositis process and not the cancer therapy itself. This impression likely underlies the observation of why many patients with persisting mucositis are prescribed an anti-fungal, anti-viral or antibiotic agent. However, because there is no clear evidence that antimicrobials shorten the course or lessen the severity of oral mucositis, their use is not recommended in mucositis guidelines [5]. Clearly, cancer therapy itself is the main driver of clinical mucositis.

The concept that mucositis is likely an ephemeral, self-limited process that is over in “2 to 4 weeks” serves to ‘disconnect’ the clinician prescribing chemo-radiation from
the patient experiencing mucositis. Indeed, Fromme et al [6] disclosed that physician reporting on adverse reactions to chemotherapy lacked both sensitivity and specificity being incongruent with patient-reported experiences. Trotti et al [7] reviewed 33 studies examining 6,181 patients with mucositis. Only 13 reported all grades of mucositis, 9 reported grades 3-4 only and only 1 reported on the quality of life. Though the most severe forms of mucositis - Grades 3-4 - are likely to be reported, dose reductions and unplanned treatment interruptions occur more frequently with less severe mucositis (23% with Grades 1, 2) than with severe mucositis (21% with Grades 3,4) [8]. These disconnects remain as hidden biases that can compromise the appropriate management of mucositis. Unfortunately, the lack of clinically effective mucositis interventions bury these disconnects from view and rendering them irrelevant. Yet an unforeseen effect of these “buried” disconnects is that the advent of effective mucositis interventions will be challenged, as some clinicians may possibly be lulled into a position of indifference. Ulcerations, erythema and the pain of mucositis patients receiving daily radiation are more likely to be noticed by the clinical staff as compared to patients receiving chemotherapy who can escape notice of the clinical staff, as they often would have navigated through the worst of their mucositis experience by the beginning of their next cycle of chemotherapy. The mouth and throat soreness of chemotherapy-induced mucositis intensifies with successive cycles, with amplification by one report, as much as 44% [9]. Recurrent bouts of mucositis double the likelihood of dose reduction and unplanned treatment interruptions [8] which directly and negatively impacts tumor kill and thereby survival. Therefore, recognition of patient-reported duration of clinical mucositis is an essential element for clinicians to sense of urgency in addressing mucositis when it occurs.

Patient-reported duration of mucositis is scattered throughout the literature and generally is addressed as an ancillary point of discussion. It is difficult to find a single reference detailing patient-reported duration of clinical mucositis in context of the multiple treatment scenarios. In practice, there are three clinical treatment scenarios of significance that are associated with the development of mucositis: (a) myeloablative conditioning in hematopoietic stem-cell transplant (HSCT), (b) multicycle chemotherapy and (c) radiation therapy with or without chemotherapy. Treatment-specific illustrations of the duration of patient-reported oral mucositis (PROM) are shown in Table 1. First, for HSCT patients (Table 1a) typically receiving single myeloablative doses of chemotherapy and irradiation, the painful mouth throat soreness affecting eating and drinking begins on day 2, with erosions and ulcerations appearing day 5-7 of oral mucositis. The peak mouth-throat soreness spans an additional 2-3 days before slowly declining over the following 18 days, [10] with an extrapolated return to baseline by day 46. Kushner et al [11] reported that patient-reported return to baseline for this cohort may take up to 60 days following myeloablative therapy. Nearly 100% of these patients experience grade 3 to 4 oral mucositis. Secondly, patients receiving the standard 6 to 7 week (42-49 days) radiation treatment for head and neck cancer can experience multiple grades of mucositis over 70 day period (Table 1b) [3,4]. With combined chemo-radiation, clinical mucositis will persist up to 84 days, and on occasion beyond [4]. Two years following chemo-radiation, a prior episode of mucositis-related inflammation contributes to chronically persistent difficulty in swallowing (confirmed by video fluoroscopy) that negatively impacts the patient-reported quality of life [12].

Lastly, and perhaps the most complicated patient group, is that of patients receiving single doses of multiple chemotherapeutic agents in 4 to 6 cycles. In this patient group mucositis experience varies based on the time of exposure to, and the type of agent used. In a triple regimen of cisplatin, fluorouracil and leucovorin administered over a four-day continuous infusion, the resultant episode of mucositis persisted over a period of 17 to 21 days per cycle (Table 1c) [9]. This is likely the minimal time duration of mucositis. Of course, when cycles are given weekly (as with certain regimens) the period of mucositis can be extended. Generally, chemotherapy is administered in 4 to 6 cycles, with the majority of cycles repeating every 14 to 21 days, and a minority of cycles repeated every 7 or 28 days [13]. Regardless, as mentioned earlier, the intensity of mucositis ulceration and patient-reported pain amplifies with successive cycles [9].

Table 1.
Duration of Patient Reported Oral Mucositis (PROM)

<table>
<thead>
<tr>
<th>a) PROM in patients undergoing HSCT</th>
<th>(Adapted from Stiff et al [10])</th>
</tr>
</thead>
<tbody>
<tr>
<td>b) PROM in patients undergoing radiation for SCCHN</td>
<td>(Adapted from Elting et al [4])</td>
</tr>
<tr>
<td>c) PROM in patients undergoing chemotherapy</td>
<td>(Adapted from Chi et al [9])</td>
</tr>
</tbody>
</table>

Harmonizing data points in terms of a mean mucositis score (for the y-axis) over a period of 84 days (as the x-axis) provides a perspective on the duration (Table 2) of clinical (symptomatic) mucositis. Table 2a compiles all three scenarios offering a contrast of the experience of mucositis in terms of time. For patients receiving multiple cycles of chemotherapy (Table 2b), recurrent episodes of ever-worsening mucositis can be daunting.
By far the longest periods of mucositis experienced are in patients receiving combined chemo-radiation where symptoms can persist beyond 80 days, while the shortest period is among patients receiving myeloablative therapy for HSCT with symptoms that extrapolate out to 46 days. Of the 400,000 patients [14] developing oral mucositis annually, approximately 55,000, or 14%, are patients with head and neck cancer many of them requiring combined chemo-radiation [15]. An additional 6,300, [16] or 1.6% of all oral mucositis patients underwent HCST. The remaining 84.4% largely consists of patients receiving multiple cycles of chemotherapy who develop mucositis on successive cycles [9].

Table 3.
Duration in days of Clinically Significant Oral Mucositis

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Days of Mucositis</th>
<th>Percent Patients Affected</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myeloablative Therapy HSCT</td>
<td>46-60 days</td>
<td>1.6%</td>
<td>Stiff et al. [10], Kushner et al. [11]</td>
</tr>
<tr>
<td>Radiation +/- Chemotherapy</td>
<td>&gt; 70-84 days</td>
<td>13.8%</td>
<td>Elting et al [3,4,8]</td>
</tr>
<tr>
<td>Multiple Cycle Chemotherapy</td>
<td>68 -102 days</td>
<td>84.6%</td>
<td>Chi et al. [10]</td>
</tr>
</tbody>
</table>

Thus, the actual duration of mucositis (Table 3) is as long as 46 to 60 days in HSCT patients, more than 84 days in patients receiving combined chemo-radiation and, in the vast majority of patients receiving four to six cycles of chemotherapy, there can be 68 to 102 days of clinical mucositis to endure.

Table 2.
Composite of Patient Reported Oral Mucositis (PROM)

Conclusion

In the supportive care of cancer treatment patients, the duration of mucositis should not be a trivial point. Rather, if one takes into account the real-world timing of common cancer treatment scenarios, then the duration of mucositis experienced by patients should be a clear point of regard by oncologists. It should be appreciated that patients undergoing HSCT will experience mucositis for 46 to 60 days, patients receiving radiation for head and neck cancer will likely suffer mucositis for more than 80 days, and those receiving four to six cycles of chemotherapy will endure 68 to 102 days of mucositis cumulatively throughout their treatment. Notwithstanding other sequelae of mucositis (e.g., systemic infections, dose reductions, increased costs, altered survival), this fact alone - the actual duration of mucositis - begs the use of interventions that could possibly ease the added burden on a disease process (cancer) largely viewed as life-threatening in most patients.

Details of funding sources

Supported by MMI Academic Grant 5-2014-08-15.

Acknowledgement

The author thanks Mr. Trevor Lewinson for this effort in proofreading this manuscript.

References


17. McCullough RW. New category of evidence should permit the Multinational Association of Support in Cancer Care (MASCC) to review polymerized cross-linked sucralfate paste (ProThelial) for mucositis guidelines. Oncol Discov J 2:1-6. DOI:10.7243/2052-6199-2-1.

